Want some DD? Look no further. 10-30-15 $CTIX ~

New Post Public Reply Private Reply Replies (1) Message Board
TheHound
Want some DD? Look no further.

10-30-15 $CTIX ~ Cellceutix Corp. due diligence report



$CTIX recent news

Press releases from Cellceutix - http://cellceutix.com/category/press-release/...r967e.dpbs

PR's from Yahoo:


Fri, 30 Oct 2015 12:17:00 GMT ~ How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked ...

read full: http://finance.yahoo.com/news/plays-research-...00619.html


Fri, 30 Oct 2015 11:30:00 GMT ~ Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide an update ...

read full: http://finance.yahoo.com/news/cellceutix-prov...00865.html


Mon, 26 Oct 2015 12:34:00 GMT ~ Cellceutix Due Diligence Report: False Accusations Cause Mayhem; Share Price Ready to Bounce

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Cellceutix Corp. (OTCMKTS: CTIX) a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, ...

read full: http://finance.yahoo.com/news/cellceutix-due-...00041.html


Mon, 26 Oct 2015 11:40:04 GMT ~ Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders ...

read full: http://finance.yahoo.com/news/cellceutix-requ...04556.html


Thu, 22 Oct 2015 18:28:15 GMT ~ Cellceutix Responds to Rosen Law Firm

[Marketwired] - Cellceutix Corporation , Cellceutix was created to tackle some of the worst diseases known to man. We are a company that firmly believes in the strength of our science and technology. It is our science ...

read full: http://finance.yahoo.com/news/cellceutix-resp...15404.html


$CTIX filings - Perhaps the most important section.

http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany



$CTIX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com





$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA

Business Description: Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. This trial is in it's final cohort and nearing completion. Plans for a Ph 2/3 Ovarian Cancer Study are underway. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is currently conducting a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, recently completed a successful Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Plans for a phase 3 trial are underway w/ FDA's approval. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Please click on the below link to find for more information on completed and active Human Clinical Trials.


https://www.clinicaltrials.gov/ct2/results?te...rch=Search




$CTIX share structure

## source: otcmarkets.com

Market Value: $172,528,983 a/o Oct 29, 2015
Shares Outstanding: 118,170,536 a/o Aug 26, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001



$CTIX extra dd links

Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com

## STOCK DETAILS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CTIX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CTIX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CTIX+Industry

## COMPANY NEWS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/news - http://finance.yahoo.com/q/h?s=CTIX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CTIX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CTIX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CTIX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cellceutix+Corp.&a...ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&am...eutix+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results...=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cellceutix.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cellceutix.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cellceutix.com

## FUNDAMENTALS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/compa...yword/CTIX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/financials?...-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?...rch=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CTIX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CTIX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CTIX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CTIX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CTIX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CTIX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CTIX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CTIX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CTIX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CTIX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CTIX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/st...icker=CTIX



1) UPCOMING MILESTONES / CATALYSTS

SCIENCE:

- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)

OPERATIONS:

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

2) CURRENT TRIALS:

Clinical Trials

Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1

2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4

4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5

Abbreviations:

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
cellceutix.com

**This section courtesy of Slcimmuno - Thanks brother!**






Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ed Markey's Political Future on Shaky Ground in MA

Updated Category News Views 0

Massachusetts Voters Voice Desire for Change Ever seen an old engine stutter and cough before finally quitting? That's what Ed Markey's political career is starting to feel like. A fresh poll has surfaced, casting doubt over his steady grip on his longstanding Senate seat in Massachusetts. People are yearning for fresh faces and new ideas like never before. It's as if the...

Continue Reading
USF Law Innovators: Leading AI Integration in Academics

Updated Category News Views 0

Revolutionizing Legal Academia with AI If there's one thing that's caught my eye in the realm of education, it's how some folks over at the University of San Francisco School of Law are shaking things up. These legal eagles aren't messing around with the usual, archaic ways of teaching the law. Nope, they've dove headfirst into the future by hooking their curriculum to...

Continue Reading
Médunik Canada Boosts Dravet Syndrome Support with Biocodex

Updated Category News Views 2

Breaking Down the Exclusive Médunik-Biocodex Partnership Listen, when a company like Médunik Canada, firmly rooted in Blainville, QC, throws its weight behind a rare disease drug like Diacomit®, folks in the industry take notice. Their recent handshake with Biocodex isn't just small talk; it opens doors to change how Dravet syndrome is managed across Canada. This new...

Continue Reading
4Roots Picks MSG for IT & Cybersecurity Support

Updated Category News Views 4

Tech-Boost for a Community Farm Vision Seems like everyone's buzzing about sustainability these days, and why not? It's the way forward. Take 4Roots and their Farm Campus initiative in Orlando. They've hooked up with Managed Services Group (MSG) to bolster their tech backbone, raising the stakes for their mission to shake up the food system. It's a no-nonsense...

Continue Reading
EF English Live's Approach to Workplace Confidence

Updated Category News Views 1

Pioneering English Confidence for the Global Workplace Stepping into a meeting with international partners requires more than just textbook knowledge of English. It's about confidently expressing ideas, adapting on the fly, and engaging with global colleagues. Enter EF English Live, a leader in transforming workplace communication through targeted English learning. Expert...

Continue Reading
Money Market Funds Surge to Record $7.98 Trillion

Updated Category News Views 3

When Money Talks Fast: Market Funds Smash Records Picture this: money market funds have surged to an eye-watering $7.98 trillion. That's a lot of zeros, folks. And it's not just the usual humdrum growth; we're talking a hefty $44.75 billion increase in just one week, thanks to a cocktail of government funds and prime fund muscle, as the Investment Company Institute (ICI)...

Continue Reading
PowerBank Bags Key Solar Project, Eyes Major Gains

Updated Category News Views 2

A New Milestone for PowerBank Sometimes, out of the blue, a company bags a contract that seems to shift the momentum overnight. That's what's happening with PowerBank Corporation. They've just scored a big win with a contract from SUNY Oneonta to build a 1.6 MW ground-mount solar project. Talk about striking gold in the solar energy field! A Competitive Win Procuring this...

Continue Reading
Roborock Expands into Pool Cleaning, Partners with Real Madrid

Updated Category News Views 2

Roborock's Strategic Leap at IFA 2026 Ah, Roborock—those smart folks who want to squeeze every second out of your day—even if it means they have to steam-blast your tile floor to free you up for something else. They've strutted their stuff at IFA 2026, and I'm not just talking robot vacuums clunking through living rooms. Nope. They're diving into pools now. What’s...

Continue Reading
LaserPecker Debuts U1: Innovations in UV Laser Engraving

Updated Category News Views 1

An Eye on the Future with LaserPecker's U1 This ain't your typical innovation announcement. LaserPecker is shifting the sands with their latest release, the U1, at IFA 2026 in Berlin. For anyone sick of struggling with transparent materials like glass and crystal, this thing promises to be a game-changer, boasting cutting-edge technology in UV laser engraving. While...

Continue Reading
Beko's Innovations in Appliances: Practical Gains Measured

Updated Category News Views 0

Finding Efficiency in Everyday Routines Let’s kick things off with a no-nonsense look at Beko's thrust into the heart of day-to-day living. This isn’t about bells and whistles, folks—it's about delivering real, quantifiable improvements in how appliances serve us at home. Istanbul's latest reveal is a nod to practicality. From the onset, Beko wraps its hands around...

Continue Reading

Top 5 Most Recently Viewed Articles

Biohaven's BHV-1300 Achieves Remarkable IgG Reductions in Trials

Updated Category News Views 240

Biohaven's Exciting Advances with BHV-1300 Biohaven Ltd. has achieved impressive results in their ongoing development of BHV-1300, a potential first-in-class IgG degrader, targeting autoimmune issues effectively. This innovative small molecule approach has distinguished itself from existing monoclonal antibody treatments by demonstrating superior efficacy in reducing IgG...

Continue Reading
Settlement Agreement Details for Ithaca Energy Limited Investors

Updated Category News Views 82

Overview of Settlement Approval for Ithaca Energy Limited This notice contains crucial information for all individuals and entities, excluding certain affiliated parties, who have purchased Ithaca Energy Limited common shares in the secondary market. If you acquired these shares on or after October 9 and held them until after the market closed on February 24 of the...

Continue Reading
Understanding the Need for Employee Crypto Trading Policies

Updated Category News Views 160

Importance of Employee Crypto Trading Policies In an evolving financial landscape marked by cryptocurrencies, the necessity for firms to establish clear employee trading policies is paramount. A recent survey highlighted how the majority of firms remain unprepared for the compliance challenges presented by crypto trading. This article delves into the findings of the 4th...

Continue Reading
Civica Introduces Affordable Insulin Glargine in 2026

Updated Category News Views 212

Civica to Launch Affordable Long-Acting Insulin Glargine In an exciting development for diabetes management, Civica, a non-profit pharmaceutical organization, is preparing to introduce its long-acting insulin known as insulin glargine-yfgn on January 1, 2026. This new injectable will be marketed at an unprecedented list price, making it the most affordable option in the...

Continue Reading
Premium Income Corporation Reveals Monthly Shareholder Payouts

Updated Category News Views 136

Premium Income Corporation Monthly Distribution Announcement Premium Income Corporation has made a significant announcement regarding its monthly distributions, creating excitement among its shareholders. This monthly payout is set for December, generating anticipation as many look forward to the benefits of their investments. Details of the Monthly Distribution The...

Continue Reading